CTLA4 and melanoma: CTLA-4 mAb lost its therapeutic efficacy against established melanomas, colon cancers, and sarcomas in mice that were reared under germ-free conditions or that had been raised in specific pathogen-free environment and then treated with multiple broad-spectrum antibiotics to sterilize the gut.